Active Biotech: Interim report January - March 2017
Laquinimod
-
The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
-
The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
-
The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
-
Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)
ANYARA
-
Project proceeding according to plan
Tasquinimod, paquinimod and SILC
-
Out-licensing activities are continuing
-
The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
-
Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
-
Product patent for SILC substances granted by the European Patent Office
Financial summary
SEK M | Jan.-Mar. | Full-year | ||
2017 | 2016 | 2016 | ||
Net sales | 4.7 | 3.9 | 19.0 | |
Operating loss | -14.6 | -16.1 | -55.1 | |
Loss after tax | -15.8 | -16.8 | -59.6 | |
Loss per share, before and after dilution (SEK) | -0.16 | -0.19 | -0.65 | |
Cash and cash equivalents (at close of period) | 62.7 | 76.5 | 77.7 | |
-
Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 |
Active Biotech AB
(Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com .
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
Upcoming Life Sciences Events
- April 2024
- Pharma-Biotech Product & Company Valuation - An Introductory
- Basel: Swiss Biotech Day 2024
- London: BioTrinity 2024